Category
Experimental & Other
Experimental compounds and miscellaneous research peptides.
ARA-290
ARA-290 (Cibinetide) — EPO Helix B-Derived Tissue Protective Peptide
Synthetic 11-amino-acid peptide derived from EPO helix B. Activates innate repair receptor without erythropoiesis. FDA Orphan Drug status for sarcoidosis neuropathy.
B7-33
B7-33 — Single-Chain Relaxin Mimetic RXFP1 Agonist
Synthetic 33-amino-acid single-chain derivative of human relaxin-2 B-chain. Functionally selective RXFP1 agonist with anti-fibrotic and cardioprotective effects in animal models.
BAM15
BAM15 — Mitochondrial Protonophore Uncoupler
Small-molecule mitochondrial protonophore that uncouples oxidative phosphorylation. Animal obesity and metabolic disease data only. Not a peptide. No human trial.
HGH Fragment 176-191
HGH Fragment 176-191 (AOD-9604, hexadecapeptide)
A 16-amino-acid C-terminal fragment of human growth hormone targeting fat metabolism through b3-adrenergic signaling. Animal models showed weight loss. Human Phase 2b trials failed to demonstrate efficacy. Not FDA-approved.
Lanreotide
Lanreotide (Somatuline Depot, Somatuline Autogel)
Long-acting somatostatin analog FDA-approved for acromegaly (2007), GEP-NETs (2014), and carcinoid syndrome (2017); Cipla generic 2024.
Larazotide Acetate
Larazotide acetate (INN-202, AT-1001)
Tight junction regulator and zonulin antagonist for celiac disease; Phase 3 CedLara trial discontinued by 9 Meters Biopharma September 2023.
Linaclotide
Linaclotide (Linzess, Constella)
Guanylate cyclase-C agonist FDA-approved August 30, 2012 for IBS-C and CIC; pediatric functional constipation indication added June 2023.
Mecasermin
Mecasermin (rhIGF-1, Increlex)
Recombinant human IGF-1 FDA-approved August 2005 for severe primary IGF-1 deficiency in pediatric patients; Eton acquisition December 2024.
Methylene Blue
Methylthioninium Chloride
A 150-year-old textile dye and the only FDA-approved treatment for methemoglobinemia. Repurposed as a mitochondrial electron carrier with off-label cognitive and longevity use that is not supported by Phase 3 data.
O-304
O-304 — Pan-AMPK Activator Small Molecule
Small-molecule pan-AMPK activator developed by Betagenon. Phase 2a complete in T2D with positive metabolic and cardiovascular effects. Not a peptide. Not FDA-approved.
Octreotide
Octreotide (Sandostatin, Mycapssa, Bynfezia)
Cyclic octapeptide somatostatin analog FDA-approved October 21, 1988 for acromegaly, NETs, carcinoid syndrome, and VIPomas.
Pasireotide
Pasireotide (Signifor, Signifor LAR)
Multi-receptor somatostatin analog (SSTR1/2/3/5) FDA-approved for Cushing's disease (Dec 2012) and acromegaly (Dec 2014); diabetes-inducing.
Pegvisomant
Pegvisomant (Somavert)
Pegylated GH analog acting as GH receptor antagonist, FDA-approved 2003 for acromegaly with inadequate surgery/radiation response.
PHDP5
PHDP5 — Pleckstrin Homology Domain Peptide 5 from Dynamin 1
Synthetic peptide derived from the pleckstrin homology domain of dynamin 1. Inhibits dynamin-microtubule binding and rescues synaptic transmission in tau-loaded models. Mouse Alzheimer's-model data only.
Plecanatide
Plecanatide (Trulance)
Uroguanylin-analog GC-C agonist FDA-approved January 19, 2017 for CIC and January 24, 2018 for IBS-C; food-flexible dosing.
PNC-27
PNC-27 — p53/HDM-2 Binding Domain Anti-Cancer Peptide
Synthetic 32-amino-acid peptide combining the HDM-2 binding domain of p53 with a membrane-residency signal. Selectively kills cancer cells through membrane disruption. No FDA approval.
Experimental and Research Peptides
This category covers peptides that do not fit the major mechanism classes. Some are early-stage academic compounds with no completed Phase 1 trial. Others are licensed in a single country and unrecognized everywhere else. A few have been withdrawn from development.
Several are first-in-class. 5-Amino-1MQ is an NNMT (nicotinamide N-methyltransferase) inhibitor studied preclinically for fat-cell senescence and metabolic disease. ACE-031 is a soluble activin receptor IIB studied for Duchenne muscular dystrophy and discontinued by Acceleron after two epistaxis events in the Phase 2 trial. AICAR is an AMPK activator that crossed into doping use before completing any therapeutic trial.
Others are repurposing candidates. BAM15 is a mitochondrial uncoupler in early animal studies for obesity, with no human data. B7-33 is a relaxin-receptor agonist studied for fibrosis. ARA-290 is a non-erythropoietic erythropoietin derivative with completed Phase 2 trials for neuropathic pain.
The evidence tier in this category is overwhelmingly preclinical or early clinical. Several entries have no human safety data. The category is the right place to look if you want to understand what is being studied beyond the well-known peptide names. It is the wrong place to find a compound for personal use. Many of these substances are research chemicals only and have no regulatory path to human use anywhere in the world.
Each entry on PeptScope names the developer, the trial program if one exists, the reason for any discontinuation, and the WADA status where relevant.